Peripheral, Central, and Chemotherapy-Induced Neuropathic Changes in Pancreatic Cancer

Medicine, Neurology, Oncology,
pancreatic cancer   neuropathic changes   chemotherapy-induced neuropathy   neural remodeling   neuropathic pain  

Neuropathic Changes in Pancreatic Cancer Academic Background Pancreatic cancer is one of the most lethal cancers today, characterized by late diagnosis and high aggressiveness. Despite some progress in diagnosis and treatment in recent years, the five-year survival rate for pancreatic cancer remains extremely low, at only around 12%. The pathogenes...

Early Detection of Pancreatic Cancer by a High-Throughput Protease-Activated Nanosensor Assay

Chemistry, Nanoscience, Medicine, Oncology, Life Sciences, Biochemistry, Bioengineering,
pancreatic cancer   early detection   nanosensor   protease   liquid biopsy  

New Method for Early Detection of Pancreatic Cancer—A Protease-Activated Nanosensor Assay Background Pancreatic Ductal Adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths worldwide. Due to its nonspecific early symptoms, most patients are diagnosed at advanced stages, resulting in limited treatment options and poor prognosis...

Tumor Extracellular Vesicle–Derived PD-L1 Promotes T Cell Senescence Through Lipid Metabolism Reprogramming

Medicine, Oncology, Life Sciences, Cell Biology, Immunology,
tumor microenvironment   T cell senescence   lipid metabolism   PD-L1   immunotherapy  

PD-L1 in Tumor-Derived Extracellular Vesicles Promotes T Cell Senescence through Lipid Metabolism Reprogramming Academic Background In recent years, immunotherapy has shown great promise in cancer treatment, particularly in checkpoint blockade therapies targeting PD-1/PD-L1 (programmed cell death protein 1 and its ligand) and CTLA-4 (cytotoxic T-ly...

Coactivation of Innate Immune Suppressive Cells Induces Acquired Resistance Against Combined TLR Agonism and PD-1 Blockade

Medicine, Oncology, Life Sciences, Immunology,
innate immune suppressive cells   acquired resistance   TLR agonists   PD-1 blockade   tumor microenvironment   CXCL1-CXCR2 axis   polymorphonuclear myeloid-derived suppressor cells  

Mechanism of Combined Immune Checkpoint Blockade Therapy Academic Background Immune Checkpoint Blockade (ICB) is a revolutionary cancer treatment aimed at reactivating effector T cells to combat cancer. However, more than half of patients do not respond to ICB, especially those with immunologically “cold” tumors (tumors with fewer immune cells in t...

Triple Knockdown of CD11a, CD49d, and PSGL1 in T Cells Reduces CAR-T Cell Toxicity but Preserves Activity Against Solid Tumors in Mice

Medicine, Oncology, Life Sciences, Cell Biology, Immunology,
CAR-T cells   solid tumors   immunotherapy   cell adhesion   cell migration  

Study on Reducing Toxicity of CAR-T Cell Therapy for Solid Tumors Academic Background Chimeric antigen receptor T-cell (CAR-T) therapy has made significant progress in treating hematologic malignancies, but its application in solid tumors faces major challenges. Solid tumors often lack tumor-specific antigens (TSAs), and CAR-T cells may attack norm...

Selective Abrogation of S6K2 Identifies Lipid Homeostasis as a Survival Vulnerability in MAPK Inhibitor–Resistant NRAS-Mutant Melanoma

Medicine, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
NRAS-mutant melanoma   MAPK inhibitor resistance   lipid metabolism   S6K2   PPARα  

Academic Background NRAS-mutant (NRASmut) melanoma is a highly aggressive tumor type, accounting for nearly 30% of all melanoma cases. NRAS is an oncogene that persistently activates the mitogen-activated protein kinase (MAPK) signaling pathway, which plays a critical role in melanoma development. However, despite extensive research on MAPK pathway...